サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1650479

炎症性腸疾患治療の世界市場レポート 2025年

Inflammatory Bowel Disease Treatment Global Market Report 2025

出版日
ページ情報
英文 200 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
炎症性腸疾患治療の世界市場レポート 2025年
出版日: 2025年02月04日
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

炎症性腸疾患治療の市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR10.1％で402億7,000万米ドルに成長します。予測期間における成長は、研究開発活動への投資の増加、バイオシミラーへの需要の高まり、新興国市場における炎症性腸疾患の罹患率の上昇、個別化医療への需要の高まり、IBD治療における精密医療の統合などに起因すると考えられます。予測期間における主な動向としては、製品の上市・承認数の増加、IBD管理における個別化された投薬・治療計画、IBD患者の遠隔モニタリングのための遠隔医療の利用、IBDに対する微生物ベースの治療法の探求、IBD治療における価値ベースのケアモデルの採用などが挙げられます。

クローン病および潰瘍性大腸炎の有病率の大幅な増加は、炎症性腸疾患治療市場成長の主要な促進要因です。炎症性腸疾患（IBD）に分類されるクローン病や潰瘍性大腸炎は、消化管の炎症や潰瘍を伴います。これらの疾患の罹患率の増加により、腸の炎症を抑え、合併症を予防することを目的とした治療に対する需要が高まると予想されています。米国国立医学図書館が2022年3月に発表した調査によると、現在約160万人の米国人が炎症性腸疾患を患っており、米国では毎年約7万人が新たに診断されています。その結果、クローン病や潰瘍性大腸炎の有病率の増加が炎症性腸疾患治療市場の成長を促進すると予測されています。

高齢者人口の増加は、炎症性腸疾患治療市場の今後の成長を促進すると予測されています。65歳以上の高齢者で構成される高齢者人口は、炎症性腸疾患に対する高い感受性を示し、その結果、治療や処置に対する需要が増加します。このような人口動態の変化は、炎症性腸疾患治療市場の拡大に寄与すると予想されます。2022年10月に世界保健機関（WHO）が発表した報告書によると、2030年までに世界の6人に1人が60歳以上になると予想されており、2050年までに60歳以上の高齢者は世界で推定21億人になるとみられています。このように、高齢者人口の増加は炎症性腸疾患治療市場を推進する重要な要因となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界の炎症性腸疾患治療市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
  • 最終用途産業の分析
  • 世界の炎症性腸疾患治療市場の成長率分析
  • 世界の炎症性腸疾患治療市場の実績：規模と成長、2019～2024年
  • 世界の炎症性腸疾患治療市場の予測：規模と成長、2024～2029年、2034年
  • 世界の炎症性腸疾患治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界の炎症性腸疾患治療市場：薬剤クラス別、実績と予測、2019～2024年、2024～2029年、2034年
  • アミノサリチル酸塩
  • コルチコステロイド
  • TNF阻害剤
  • IL阻害剤
  • 抗インテグリン
  • JAK阻害剤
  • その他
  • 世界の炎症性腸疾患治療市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • クローン病
  • 潰瘍性大腸炎
  • 世界の炎症性腸疾患治療市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
  • 経口
  • 注射
  • 世界の炎症性腸疾患治療市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • 世界の炎症性腸疾患治療市場：アミノサリチル酸塩のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • メサラミン
  • スルファサラジン
  • バルサラジド
  • 世界の炎症性腸疾患治療市場：コルチコステロイドのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • プレドニゾン
  • ブデソニド
  • ヒドロコルチゾン
  • 世界の炎症性腸疾患治療市場：TNF阻害剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • インフリキシマブ
  • アダリムマブ
  • セルトリズマブペゴル
  • 世界の炎症性腸疾患治療市場：IL阻害剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • ウステキヌマブ
  • グセルクマブ
  • 世界の炎症性腸疾患治療市場：抗インテグリンのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • ベドリズマブ
  • ナタリズマブ
  • 世界の炎症性腸疾患治療市場：JAK阻害剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • トファシチニブ
  • フィルゴチニブ
  • 世界の炎症性腸疾患治療市場：その他のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 抗生物質
  • 免疫抑制剤
  • その他の新しい治療法

第7章 地域別・国別分析

  • 世界の炎症性腸疾患治療市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
  • 世界の炎症性腸疾患治療市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 炎症性腸疾患治療市場：競合情勢
  • 炎症性腸疾患治療市場：企業プロファイル
    • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
    • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Advanced Gastroenterology and Surgery Associates P. A. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • Atlanta Gastroenterology Associates LLC
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cedars-Sinai Medical Center
  • Celgene Corporation
  • Cleveland Clinic Foundation
  • Digestive Disease Associates of Rockland P. C.
  • Eli Lilly and Company
  • Gastrointestinal Specialists Inc.
  • Gilead Sciences Inc.
  • GlaxoSmithKline plc
  • Illinois Gastroenterology Group LLC
  • The Johns Hopkins Hospital Inc.
  • Massachusetts General Hospital
  • Mayo Clinic

第32章 世界市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 市場の最近の動向

第35章 市場の潜在力が高い国、セグメント、戦略

  • 炎症性腸疾患治療市場2029年-最も新しい機会を提供する国
  • 炎症性腸疾患治療市場2029年-最も新しい機会を提供するセグメント
  • 炎症性腸疾患治療市場2029年-成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r21653

Treatment for inflammatory bowel disease involves the use of anti-inflammatory medications commonly employed for mild to moderate cases of ulcerative colitis. Aminosalicylates, including mesalamine (Delzicol, Rowasa, among others), balsalazide (Colazal), and olsalazine, serve as anti-inflammatories, with Dipentum being one of them.

The primary drug categories in the treatment of inflammatory bowel disease encompass aminosalicylates, corticosteroids, TNF inhibitors, IL inhibitors, anti-integrin, JAK inhibitors, and other options. Aminosalicylates, a specific class of drugs, are utilized to manage and prevent flare-ups in ulcerative colitis and Crohn's disease. The mechanism of action of aminosalicylates involves inhibiting the production of cyclo-oxygenase, prostaglandin, thromboxane synthetase, platelet-activating factor synthetase, and interleukin-1 by macrophages. Both orally and via injection, treatments for inflammatory bowel disease are administered for Crohn's disease and ulcerative colitis. These medications are available through hospital pharmacies, retail pharmacies, and online pharmacies.

The inflammatory bowel disease treatment market research report is one of a series of new reports from The Business Research Company that provides inflammatory bowel disease treatment market statistics, including inflammatory bowel disease treatment industry global market size, regional shares, competitors with an inflammatory bowel disease treatment market share, detailed inflammatory bowel disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the inflammatory bowel disease treatment industry. This inflammatory bowel disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The inflammatory bowel disease treatment market size has grown strongly in recent years. It will grow from $25.26 billion in 2024 to $27.45 billion in 2025 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to increased prevalence of inflammatory bowel disease, growing demand for biologics and immunomodulators, advancements in treatment options, rising geriatric population, increased awareness aboutThe disease.

The inflammatory bowel disease treatment market size is expected to see rapid growth in the next few years. It will grow to $40.27 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to increasing investment in research and development activities, growing demand for biosimilars, rising incidence of inflammatory bowel disease in emerging markets, growing demand for personalized medicine, integration of precision medicine in IBD treatment. Major trends in the forecast period include increasing number of product launches and approvals, personalized dosing and treatment plans in IBD management, use of telemedicine for remote monitoring of IBD patients, exploration of microbiome-based therapies for IBD, adoption of value-based care models in IBD treatment.

The significant increase in the prevalence of Crohn's disease and ulcerative colitis is a key driver for the growth of the market for inflammatory bowel disease treatment. Crohn's disease and ulcerative colitis, categorized as inflammatory bowel diseases (IBD), involve inflammation and ulcers in the digestive tracts. The growing incidence of these diseases is expected to elevate the demand for treatments that aim to reduce bowel inflammation and prevent medical complications. A March 2022 research publication from the United States National Library of Medicine indicates that approximately 1. 6 million Americans presently suffer from inflammatory bowel disease, with around 70,000 new cases diagnosed annually in the USA. Consequently, the increasing prevalence of Crohn's disease and ulcerative colitis is anticipated to propel the growth of the inflammatory bowel disease treatment market.

The rise in the geriatric population is forecasted to drive the growth of the inflammatory bowel disease treatment market in the future. The geriatric population, comprising individuals aged 65 and older, exhibits a higher susceptibility to inflammatory bowel diseases, resulting in an increased demand for treatments and therapies. This demographic shift is expected to contribute to the expansion of the inflammatory bowel disease treatment market. A report from the World Health Organization (WHO) in October 2022 highlights that by the year 2030, one in six people globally is expected to be 60 or older, and by 2050, there will be an estimated 2. 1 billion people worldwide aged 60 or older. Thus, the growth of the geriatric population is a significant factor propelling the inflammatory bowel disease treatment market.

Technological advancement is a significant trend gaining traction in the inflammatory bowel disease treatment market. Major companies in this sector are focusing on AI-driven registries to achieve a competitive advantage. For example, in May 2024, Verantos, a California-based real-world evidence (RWE) company, introduced the Inflammatory Bowel Disease Pragmatic Registry, which utilizes advanced artificial intelligence to produce high-quality real-world evidence (RWE) for ulcerative colitis and Crohn's disease. This registry is designed to aid in the development of effective therapies by offering a comprehensive dataset containing over 3 billion data points related to patient care. It enables biopharma researchers to gain in-depth insights into disease severity, treatment efficacy, and clinical outcomes by analyzing both structured and unstructured data from electronic health records.

Major companies in the inflammatory bowel disease treatment market are focusing on the development of innovative products targeting larger customer bases and increasing revenue. Treatments for moderate to severe active ulcerative colitis, involving medications and sometimes surgical interventions, are a key area of innovation. In October 2023, Eli Lilly and Company, a US-based pharmaceutical company, received U. S. Food and Drug Administration (FDA) approval for Omvoh (mirikizumab-mrkz), the first interleukin-23p19 (IL-23p19) antagonist designed to treat adults with moderately to severely active ulcerative colitis (UC). Omvoh targets the IL-23 pathway, effectively blocking inflammation associated with UC. The treatment regimen involves initial infusions followed by subcutaneous self-injections during the maintenance phase.

In March 2022, Pfizer, Inc., a U. S. -based pharmaceutical and biotechnology company, acquired Arena Pharmaceuticals, Inc., for $6. 7 billion. Through this acquisition, Pfizer aims to enhance its research capabilities in the Inflammation and Immunology therapeutic area, develop therapies for immuno-inflammatory diseases, and continue the clinical development of existing drug candidates. Arena Pharmaceuticals, Inc., is a U. S. -based biopharmaceutical company specializing in the development of novel treatments for various immuno-inflammatory conditions.

Major companies operating in the inflammatory bowel disease treatment market include AbbVie Inc., Biogen Inc., Johnson & Johnson, Amgen Inc., Advanced Gastroenterology and Surgery Associates P. A., Atlanta Gastroenterology Associates LLC, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cedars-Sinai Medical Center, Celgene Corporation, Cleveland Clinic Foundation, Digestive Disease Associates of Rockland P. C., Eli Lilly and Company, Gastrointestinal Specialists Inc., Gilead Sciences Inc., GlaxoSmithKline plc, Illinois Gastroenterology Group LLC, The Johns Hopkins Hospital Inc., Massachusetts General Hospital, Mayo Clinic, Merck & Co. Inc., Mount Sinai Health System Inc., Novartis International AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Texas Digestive Disease Consultants P. A., The Oregon Clinic - Gastroenterology West P. C., Salix Pharmaceuticals Inc., Vifor Pharma AG, Zydus Pharmaceuticals (USA) Inc.

North America was the largest region in the inflammatory bowel disease treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inflammatory bowel disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the inflammatory bowel disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The inflammatory bowel disease treatment market includes revenues earned by entities by reducing the inflammation that triggers the signs and symptoms. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Inflammatory Bowel Disease Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on inflammatory bowel disease treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for inflammatory bowel disease treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The inflammatory bowel disease treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Drug Class: Aminosalicylates; Corticosteroids; TNF inhibitors; IL inhibitors; Anti-integrin; JAK inhibitors; Other Drug Classes
  • 2) By Type: Crohn's Disease; Ulcerative Colitis
  • 3) By Route Of Administration: Oral; Injectable
  • 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
  • Subsegments:
  • 1) By Aminosalicylates: Mesalamine; Sulfasalazine; Balsalazide
  • 2) By Corticosteroids: Prednisone; Budesonide; Hydrocortisone
  • 3) By TNF Inhibitors: Infliximab; Adalimumab; Certolizumab pegol
  • 4) By IL Inhibitors: Ustekinumab; Guselkumab
  • 5) By Anti-Integrin: Vedolizumab; Natalizumab
  • 6) By JAK Inhibitors: Tofacitinib; Filgotinib
  • 7) By Other Drug Classes: Antibiotics; Immunosuppressants; Other Novel Therapies
  • Companies Mentioned: AbbVie Inc.; Biogen Inc.; Johnson & Johnson; Amgen Inc.; Advanced Gastroenterology and Surgery Associates P. A.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Inflammatory Bowel Disease Treatment Market Characteristics

3. Inflammatory Bowel Disease Treatment Market Trends And Strategies

4. Inflammatory Bowel Disease Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Inflammatory Bowel Disease Treatment Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Inflammatory Bowel Disease Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Inflammatory Bowel Disease Treatment Market Growth Rate Analysis
  • 5.4. Global Inflammatory Bowel Disease Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Inflammatory Bowel Disease Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Inflammatory Bowel Disease Treatment Total Addressable Market (TAM)

6. Inflammatory Bowel Disease Treatment Market Segmentation

  • 6.1. Global Inflammatory Bowel Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Aminosalicylates
  • Corticosteroids
  • TNF inhibitors
  • IL inhibitors
  • Anti-integrin
  • JAK inhibitors
  • Other Drug Classes
  • 6.2. Global Inflammatory Bowel Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Crohn's Disease
  • Ulcerative Colitis
  • 6.3. Global Inflammatory Bowel Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oral
  • Injectable
  • 6.4. Global Inflammatory Bowel Disease Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • 6.5. Global Inflammatory Bowel Disease Treatment Market, Sub-Segmentation Of Aminosalicylates,By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Mesalamine
  • Sulfasalazine
  • Balsalazide
  • 6.6. Global Inflammatory Bowel Disease Treatment Market, Sub-Segmentation Of Corticosteroids,By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Prednisone
  • Budesonide
  • Hydrocortisone
  • 6.7. Global Inflammatory Bowel Disease Treatment Market, Sub-Segmentation Of TNF Inhibitors,By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Infliximab
  • Adalimumab
  • Certolizumab pegol
  • 6.8. Global Inflammatory Bowel Disease Treatment Market, Sub-Segmentation Of IL Inhibitors,By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Ustekinumab
  • Guselkumab
  • 6.9. Global Inflammatory Bowel Disease Treatment Market, Sub-Segmentation Of Anti-Integrin,By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Vedolizumab
  • Natalizumab
  • 6.10. Global Inflammatory Bowel Disease Treatment Market, Sub-Segmentation Of JAK Inhibitors,By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Tofacitinib
  • Filgotinib
  • 6.11. Global Inflammatory Bowel Disease Treatment Market, Sub-Segmentation Of Other Drug Classes,By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Antibiotics
  • Immunosuppressants
  • Other Novel Therapies

7. Inflammatory Bowel Disease Treatment Market Regional And Country Analysis

  • 7.1. Global Inflammatory Bowel Disease Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Inflammatory Bowel Disease Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Inflammatory Bowel Disease Treatment Market

  • 8.1. Asia-Pacific Inflammatory Bowel Disease Treatment Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Inflammatory Bowel Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Inflammatory Bowel Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Inflammatory Bowel Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Inflammatory Bowel Disease Treatment Market

  • 9.1. China Inflammatory Bowel Disease Treatment Market Overview
  • 9.2. China Inflammatory Bowel Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Inflammatory Bowel Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Inflammatory Bowel Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Inflammatory Bowel Disease Treatment Market

  • 10.1. India Inflammatory Bowel Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Inflammatory Bowel Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Inflammatory Bowel Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Inflammatory Bowel Disease Treatment Market

  • 11.1. Japan Inflammatory Bowel Disease Treatment Market Overview
  • 11.2. Japan Inflammatory Bowel Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Inflammatory Bowel Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Inflammatory Bowel Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Inflammatory Bowel Disease Treatment Market

  • 12.1. Australia Inflammatory Bowel Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Inflammatory Bowel Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Inflammatory Bowel Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Inflammatory Bowel Disease Treatment Market

  • 13.1. Indonesia Inflammatory Bowel Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Inflammatory Bowel Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Inflammatory Bowel Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Inflammatory Bowel Disease Treatment Market

  • 14.1. South Korea Inflammatory Bowel Disease Treatment Market Overview
  • 14.2. South Korea Inflammatory Bowel Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Inflammatory Bowel Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Inflammatory Bowel Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Inflammatory Bowel Disease Treatment Market

  • 15.1. Western Europe Inflammatory Bowel Disease Treatment Market Overview
  • 15.2. Western Europe Inflammatory Bowel Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Inflammatory Bowel Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Inflammatory Bowel Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Inflammatory Bowel Disease Treatment Market

  • 16.1. UK Inflammatory Bowel Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Inflammatory Bowel Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Inflammatory Bowel Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Inflammatory Bowel Disease Treatment Market

  • 17.1. Germany Inflammatory Bowel Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Inflammatory Bowel Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Inflammatory Bowel Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Inflammatory Bowel Disease Treatment Market

  • 18.1. France Inflammatory Bowel Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Inflammatory Bowel Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Inflammatory Bowel Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Inflammatory Bowel Disease Treatment Market

  • 19.1. Italy Inflammatory Bowel Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Inflammatory Bowel Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Inflammatory Bowel Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Inflammatory Bowel Disease Treatment Market

  • 20.1. Spain Inflammatory Bowel Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Inflammatory Bowel Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Inflammatory Bowel Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Inflammatory Bowel Disease Treatment Market

  • 21.1. Eastern Europe Inflammatory Bowel Disease Treatment Market Overview
  • 21.2. Eastern Europe Inflammatory Bowel Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Inflammatory Bowel Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Inflammatory Bowel Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Inflammatory Bowel Disease Treatment Market

  • 22.1. Russia Inflammatory Bowel Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Inflammatory Bowel Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Inflammatory Bowel Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Inflammatory Bowel Disease Treatment Market

  • 23.1. North America Inflammatory Bowel Disease Treatment Market Overview
  • 23.2. North America Inflammatory Bowel Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Inflammatory Bowel Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Inflammatory Bowel Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Inflammatory Bowel Disease Treatment Market

  • 24.1. USA Inflammatory Bowel Disease Treatment Market Overview
  • 24.2. USA Inflammatory Bowel Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Inflammatory Bowel Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Inflammatory Bowel Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Inflammatory Bowel Disease Treatment Market

  • 25.1. Canada Inflammatory Bowel Disease Treatment Market Overview
  • 25.2. Canada Inflammatory Bowel Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Inflammatory Bowel Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Inflammatory Bowel Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Inflammatory Bowel Disease Treatment Market

  • 26.1. South America Inflammatory Bowel Disease Treatment Market Overview
  • 26.2. South America Inflammatory Bowel Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Inflammatory Bowel Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Inflammatory Bowel Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Inflammatory Bowel Disease Treatment Market

  • 27.1. Brazil Inflammatory Bowel Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Inflammatory Bowel Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Inflammatory Bowel Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Inflammatory Bowel Disease Treatment Market

  • 28.1. Middle East Inflammatory Bowel Disease Treatment Market Overview
  • 28.2. Middle East Inflammatory Bowel Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Inflammatory Bowel Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Inflammatory Bowel Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Inflammatory Bowel Disease Treatment Market

  • 29.1. Africa Inflammatory Bowel Disease Treatment Market Overview
  • 29.2. Africa Inflammatory Bowel Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Inflammatory Bowel Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Inflammatory Bowel Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Inflammatory Bowel Disease Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Inflammatory Bowel Disease Treatment Market Competitive Landscape
  • 30.2. Inflammatory Bowel Disease Treatment Market Company Profiles
    • 30.2.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Advanced Gastroenterology and Surgery Associates P. A. Overview, Products and Services, Strategy and Financial Analysis

31. Inflammatory Bowel Disease Treatment Market Other Major And Innovative Companies

  • 31.1. Atlanta Gastroenterology Associates LLC
  • 31.2. Boehringer Ingelheim International GmbH
  • 31.3. Bristol-Myers Squibb Company
  • 31.4. Cedars-Sinai Medical Center
  • 31.5. Celgene Corporation
  • 31.6. Cleveland Clinic Foundation
  • 31.7. Digestive Disease Associates of Rockland P. C.
  • 31.8. Eli Lilly and Company
  • 31.9. Gastrointestinal Specialists Inc.
  • 31.10. Gilead Sciences Inc.
  • 31.11. GlaxoSmithKline plc
  • 31.12. Illinois Gastroenterology Group LLC
  • 31.13. The Johns Hopkins Hospital Inc.
  • 31.14. Massachusetts General Hospital
  • 31.15. Mayo Clinic

32. Global Inflammatory Bowel Disease Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Inflammatory Bowel Disease Treatment Market

34. Recent Developments In The Inflammatory Bowel Disease Treatment Market

35. Inflammatory Bowel Disease Treatment Market High Potential Countries, Segments and Strategies

  • 35.1 Inflammatory Bowel Disease Treatment Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Inflammatory Bowel Disease Treatment Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Inflammatory Bowel Disease Treatment Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer